Abarceo Pharma
Novel therapeutics of type-2 diabetes
- CEO: Kristian Hansen
- First investment year: 2021
- Fund: South
- Business sector: Life Science
Abarceo Pharma
Abarceo Pharma has identified a novel treatment of type-2 diabetes which addresses the disease at the root and allows patients to produce their insulin again, naturally.